Home » Newsletters » BioWorld Science

BioWorld Science

May 11, 2015

View Archived Issues

Cancer Genetics and Moffitt to study genetic variants as predictors for chemotherapy side effects

Pernix completes pharmacokinetic equivalence study of ZX-007

Zhejiang Beta Pharma patents PARP-1 inhibitors

Bayer discloses results for BAY-1143572

Tiziana licenses anticancer stem cell agent from Cardiff University

Wockhardt divulges new antibacterials

Otonomy completes enrollment in trial of AuriPro for otitis media with tympanostomy tubes

Adaptive Biotechnologies completes Series F financing round

Phase I/II trial to investigate combination of PLX-3397 and pembrolizumab in solid tumors

Sanofi reveals highlights of first quarter 2015

Lacripep for aqueous-deficient dry eye treatment

Juno Therapeutics and Fate Therapeutics collaborate to improve T-cell immunotherapeutics

Claudin-1 as a potential target for HCV infection

Enyo gains access to Poxel's FXR agonist program for use in liver-based infections

Phase I results support further evaluation of JZP-386

Clcn7G213R-siRNA rescues osteoclast function in ADO2 model

Discovery and first preclinical data disclosed for novel ERalpha inhibitor AZD-9496

ProMetic selects C1-INH for development

Hyperion Therapeutics acquired by Horizon Pharma

FDA lifts clinical hold on NeuroDerm's ND-0612

Infinity patents PI3Kdelta inhibitors

Jiangsu Hengrui Medicine discloses MEK1 inhibitors

Daewoong introduces novel antifungals

West Nile virus vaccine candidate begins phase I trial

ArQule and Beryllium Discovery collaborate in immune-oncology

Novel mouse model for endometrial cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...